Late-Breaking Science – Scientific Sessions 2024

Saturday, November 16, 2024, 8:30 AM – 9:45 AM
LBS.01 in Program Planner

• BPROAD - Effects of Intensive Blood Pressure Control in Patients with Type 2 Diabetes (BPROAD)
• SUMMIT - Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
• Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study

Saturday, November 16, 2024, 1:30 PM – 2:45 PM
LBS.02 in Program Planner

• VANISH2 - Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy (VANISH2)
• OPTION - Randomized Comparison of Left Atrial Appendage Closure with Oral Anticoagulation after Catheter Ablation for Atrial Fibrillation (OPTION)
• BRAIN AF - Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation (BRAIN AF)

Saturday, November 16, 2024, 3:15 PM – 4:30 PM
LBS.03 in Program Planner

• PHARM-HF A&F - Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study)
• SEISMIC HF-I - Novel AI to Assess Intracardiac Filling Pressure: The Non-invasive SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study
• AI-ECHO - Artificial Intelligence-based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial
• PanEcho: Complete AI-enabled echocardiography interpretation with multi-task deep learning

Sunday, November 17, 2024, 8:00 AM – 9:15 AM
LBS.04 in Program Planner

• GLORIOUS - Efficacy of Restrictive versus Liberal Oxygenation in Patients undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial (GLORIOUS)
• Efficacy of a Glucagon-Like Peptide-1 Agonist in Patients undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial (GLORIOUS)
• ENBALV - Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early after Surgical Bioprosthetic Valve Replacement: ENBALV trial
• The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction. The results of the spironolactone factorial.

Sunday, November 17, 2024, 3:30 PM – 4:45 PM
LBS.06 in Program Planner

• TOPSPIN - A Three-arm Randomized Trial For Treatment Optimisation Of Blood Pressure With Single-pill Combinations In India
• NUDGE-FLU - Electronic Nudges to Increase Influenza Vaccination among Patients with History of Myocardial Infarction: Insights from 3 Randomized Clinical Trials Enrolling >2 Million Patients (NUDGE-FLU)
• ZODIAC -  Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies after Acute Coronary Syndrome (ZODIAC)
• MHYH - Preliminary Results of Randomized Trial of New Versus Reconditioned Pacemakers for Patients Unable to Obtain a New Device in Low and Middle-Income Countries: The My Heart Your Heart (MHYH) Randomized Trial

Monday, November 18, 2024, 8:00 AM – 9:15 AM
LBS.06 in Program Planner

• ENDEAVOR - Myeloperoxidase Inhibition with Mitiperstat in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Primary Results from the ENDEAVOR Randomized Clinical Trial
• SARAH - Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial – The SARAH Trial
• Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability, and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)
• REALIZE-K - Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial

Monday, November 18, 2024, 9:45 AM – 11:00 AM
LBS.07 in Program Planner

• PROMPT-AF - Comparison of Linear Ablation Plus Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results from the PROMPT-AF Randomized Trial
• CRRF-PeAF - Cryoballoon Ablation versus Radiofrequency Ablation in Patients with Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Non-inferiority Clinical Trial
• TRIM-AF - Randomized Controlled Trial of Metformin and Lifestyle/Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial
• ARREST-AF - Aggressive Risk factor REduction STudy for Atrial Fibrillation (ARREST-AF) implications for ablation outcomes: A Randomized Clinical Trial

Monday, November 18, 2024, 1:30 PM – 2:45 PM
LBS.08 in Program Planner

• ALPACAR - Phase 2 Trial of Zerlasiran: Multiple doses of a Short-Interfering RNA Targeting Lipoprotein(a) over 60 weeks
• KRAKEN - A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)
• BROOKLYN - Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (BROOKLYN)

Abstracts and presentations are embargoed for release until the date and time of presentation at Scientific Sessions 2024. Information may not be released before then. Failure to honor embargo policies will result in the trial being withdrawn on site and barred from presentation. Any breach of the embargo policy may adversely affect participation in future AHA Sessions. Clinical trial sponsors must comply with the embargo guidelines established by the American Heart Association.

We understand that the sponsoring organization may be required to release top-line results in order to follow SEC (Security Exchange Commission) regulations, however, AHA must be notified before ANY release of information. Any level of information released without approval will be considered an embargo break. Please contact Mary Lu Hare if you are preparing a press release or for any questions.